ELLKF yields 35.31% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, ELLKF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ELLKF + PFE for your $10,000?
Ellaktor S.A., through its subsidiaries, engages in the construction and quarrying, wind energy, concession, environment, and real estate development businesses in Greece, other European countries, Gulf countries, the Americas, and Australia. The company operates through five segments: Construction, Concessions, Renewable Energy Sources (RES), Environment, and Real estate Development. It constructs bridges, motorways, metro projects, biological treatment plants, natural gas pipelines, refineries, shopping centers, casinos, tourist and hotel units, cultural centers, hospitals, airports, Olympic and athletic complexes, railway projects, tunnels, dams, port projects, energy production stations, electromechanical projects, etc.; and logistics, office, residential, industrial, and educational buildings. The company is also involved in the waste management and energy production, which include design, construction, and operation of waste treatment plant, as well as offers alternative fuel production and biomass exploitation projects. In addition, it develops, constructs, and operates wind farms; provides real estate development and services, which consists of retail parks, entertainment centers, residential complexes, exhibition centers, and offices and mixed use buildings, as well as offers consultancy and services to third parties. The company was formerly known as ELLINIKI TECHNODOMIKI TEB SA and changed its name to Ellaktor S.A. in 2008. The company is headquartered in Athens, Greece.
Full ELLKF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.